Press release - 28/04/2022 Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
Press release - 03/11/2015 CureVac raises $110 Million in a private placement CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
Article - 18/01/2010 New substance helps PKU patients enjoy food For many decades, a special low-protein (low-phenylalanine) diet has been the only way of treating children suffering from phenylketonuria (PKU) that effectively prevents them from developing severe impairments in mental function. However, this type of diet is not very tasty and it is often difficult to get children to cooperate. A paediatrician from Reutlingen, Prof. Dr. Friedrich Trefz, has now been able to show that the substance sapropterin…https://www.gesundheitsindustrie-bw.de/en/article/news/new-substance-helps-pku-patients-enjoy-food
Article - 28/07/2008 25 amino acids against avian influenza About a year ago Prof. Dr. Martin Schwemmle and his team at the University Hospital of Freiburg discovered a new starting point in the fight against the H5N1-virus. In the meantime the scientists are working together with the company Pike Pharma to develop a compound.https://www.gesundheitsindustrie-bw.de/en/article/news/25-amino-acids-against-avian-influenza
Article - 09/12/2013 KVART – a hospital bed with built-in intelligence Exercise is the best medicine! this was the maxim adopted by Dr. Clemens Gutknecht and Dr. Josef Schönberger when they were investigating the treatment remobilisation and care of bedridden patients. The findings of the two experienced neurologists led to the development of a concept for an intelligent hospital bed. Based on a patented technology and quantitative market potential estimates Gutknecht and Schönberger have established KVART GmbH in…https://www.gesundheitsindustrie-bw.de/en/article/news/kvart-a-hospital-bed-with-built-in-intelligence
Press release - 25/08/2008 Cross-border fight against cancer The Lake Constance region offers a broad range of cancer therapies and is home to several institutes and companies that are dealing with cancer research. The BioLAGO biotechnology network offers them a joint platform for co-operation and exchange of information.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cross-border-fight-against-cancer
Article - 14/01/2009 Strict requirements for the market approval of tissue engineering products New regulations for the marketing approval of advanced therapy medicinal products have applied in the EU since December 2008. Prof. Sabine Kloth from TÜV SÜD Product Service GmbH is an expert in materials of animal origin and has been closely following the formulation of the ATMP Regulation. https://www.gesundheitsindustrie-bw.de/en/article/news/strict-requirements-for-the-market-approval-of-tissue-engineering-products
Article - 18/12/2012 Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie? Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu
Article - 28/02/2008 Gilbert Gorr - a great fan of the moss Physcomitrella patens Dr. Gilbert Gorr has been fascinated by the moss Physcomitrella patens for many years in fact it occupies a great deal of his waking moments. The enthusiasm with which the CSO of greenovation Biotech GmbH talks about the key object of his work is both intoxicating and contagious. The latest discovery The moss produces a therapeutic antibody that is far more effective than its predecessors created in animal cell cultures.https://www.gesundheitsindustrie-bw.de/en/article/news/gilbert-gorr-a-great-fan-of-the-moss-physcomitrella-patens
Press release - 10/12/2018 High distinction for stem cell researcher Andreas Trumpp This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
Article - 02/08/2016 Can the ticking Huntington clock be stopped? An early phase clinical study involving thirty-six Huntington’s disease (HD) patients is currently underway to investigate whether a method called gene silencing can cure the disease. If the gene that causes the disease can be turned off, it would be the first step towards a treatment that not only fights symptoms but actually treats the causes of HD, hence providing a cure. https://www.gesundheitsindustrie-bw.de/en/article/news/can-the-ticking-huntington-clock-be-stopped
Company profile - 18/07/2016 mbits imaging GmbH – mobile app in the field of radiology Trying to get a second opinion from a medical colleague who is at home preparing dinner may be quite a challenge, especially when the colleague does not have access to the necessary image data. This has now become easier in the field of radiology thanks to a mobile app called mRay, which provides a reliable way for radiologists to share medical images on mobile devices. https://www.gesundheitsindustrie-bw.de/en/article/news/mbits-imaging-gmbh-mobile-app-in-the-field-of-radiology
Article - 14/01/2013 Boehringer takes a deep breath: a look into the company’s respiratory R&D pipeline At its 3rd International Research & Development (R&D) press conference, Boehringer Ingelheim gave journalists insights into its R&D pipeline. Around 200 scientists at the company’s site in Biberach are investigating new treatment options for patients with COPD (chronic obstructive pulmonary disease), asthma, idiopathic lung fibrosis, lung cancer and other respiratory diseases. In addition, the researchers are also focusing on the…https://www.gesundheitsindustrie-bw.de/en/article/news/boehringer-takes-a-deep-breath-a-look-into-the-company-s-respiratory-r-d-pipeline
Dossier - 05/10/2011 Biosimilars: follow-on biologics of innovator biopharmaceutical products As blockbuster biopharmaceuticals go off patent, biosimilars are increasingly competing with them for a market share. However, the production of biosimilars is rather complex and costly. The approval of biosimilars is also subject to many hurdles. Their introduction to the very expensive biopharmaceuticals market is often associated with marginal price reductions.https://www.gesundheitsindustrie-bw.de/en/article/dossier/biosimilars-follow-on-biologics-of-innovator-biopharmaceutical-products
Article - 05/04/2008 Successful cooperation between science and industry (II) In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform. https://www.gesundheitsindustrie-bw.de/en/article/news/successful-cooperation-between-science-and-industry-ii
Article - 29/08/2011 Ute Schepers – the therapeutic potential of small RNAs and molecular transporters Small RNAs can specifically interfere with cellular mechanisms; or more precisely, with the cells’ protein biosynthesis machinery. Scientists have therefore decided to exploit this potential by using small RNAs against cancer cells or cells damaged in other ways. But the question arises as to how the small RNAs can reach the site where their role is to prevent the generation of dangerous proteins. Dr. Ute Schepers and her team from the Karlsruhe…https://www.gesundheitsindustrie-bw.de/en/article/news/ute-schepers-the-therapeutic-potential-of-small-rnas-and-molecular-transporters
Article - 08/07/2021 Individual operation risk assessment by the Cognitive Medical Assistant Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…https://www.gesundheitsindustrie-bw.de/en/article/news/individual-operation-risk-assessment-cognitive-medical-assistant
Press release - 04/01/2018 CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Press release - 26/05/2011 High Scientific Level at the Second International Workshop about Drug-Drug Interactions The organisation team of the Second International DDI drug-drug interactions Workshop has expressed great satisfaction with the course of the scientific meeting. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts scientists members of the industry and regulatory bodies regarding DDI affairs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-scientific-level-at-the-second-international-workshop-about-drug-drug-interactions
Article - 21/02/2018 HepaRegeniX – a start-up is taking it up a step! HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-a-start-up-is-taking-it-up-a-step
Article - 16/04/2012 Pharma 2.0: towards paperless production Before electronic solutions existed lorries were needed to ship new drug applications which often comprised 500000 or so pages. Thanks to IT this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. Markus Roemer CEO of Ravensburg-based comes compliance services supports companies in implementing legal guidelines in this area. In the following interview Roemer talks…https://www.gesundheitsindustrie-bw.de/en/article/news/pharma-2-0-towards-paperless-production
Dossier - 31/03/2014 Peptides – diverse molecules of life Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Despite some drawbacks, peptides are gaining in importance as candidates for drugs…https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
Article - 09/01/2012 Nutritional medicine: Can certain foods help treat cancer? Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.https://www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
Article - 17/10/2011 Papillomaviruses as cancer-causing agents and how they can be fought off Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…https://www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off